Company: LCTX
Filing Date: 2025-06-11
Form Type: DEFA14A
Source: 0000950170-25-084916
Chunk: 2

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-06-11
Form: DEFA14A
Chunk 2
---
 financial reporting issue, or (iii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event of the type described in Item 304(a)(1)(v) of Regulation S-K. We furnished Moss Adams with a copy of the disclosure in Item 4.01 of the Auditor Change 8-K and requested that Moss Adams furnish us with a letter addressed to the SEC stating whether Moss Adams agrees with the statements made by us in such Item 4.01, and if not, stating the respects in which it does not agree. Moss Adams furnished such a letter, a copy of which is filed as Exhibit 16.1 to the Auditor Change 8-K. As a result of the foregoing, with respect to Proposal 2 described in the Proxy Statement (the “Auditor Ratification Proposal”), our Board is requesting that our shareholders ratify the appointment of Baker Tilly as our independent registered public accounting firm for the fiscal year ending December 31, 2025, and our Board unanimously recommends you vote “FOR” the ratification of the appointment of Baker Tilly as our independent registered public accounting firm for the fiscal year ending December 31, 2025. All references to the ratification of the appointment of Moss Adams as our independent registered public accounting firm in the Proxy Statement are hereby updated to refer to the ratification of the appointment of Baker Tilly as our independent registered public accounting firm. We expect that a representative of Baker Tilly will be present at the Meeting, in person or by phone, and will have an opportunity to make a statement if he or she so desires and may respond to appropriate questions from shareholders. Important Voting Information Proxy cards and voting instructions previously returned by stockholders and votes previously cast by shareholders will remain valid and will be used at the Meeting unless changed or revoked. We will consider votes “FOR” or “AGAINST” the Auditor Ratification Proposal as votes “FOR” or “AGAINST,” respectively, the ratification of the appointment of Baker Tilly, as the successor accounting

firm following the merger with Moss Adams, as our independent registered public accounting firm for the fiscal year ending December 31, 2025. Similarly, we will consider abstentions on the Auditor Ratification Proposal as abstentions on the vote to ratify the appointment of Baker Tilly as our independent registered public accounting firm for the fiscal year ending December